Use of PARP Inhibitors for Ovarian Cancer

Presented by:
Deborah K. Armstrong
Search for other papers by Deborah K. Armstrong in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 19: Issue 5.5
Online Publication Date:
17 May 2021
DOI:
https://doi.org/10.6004/jnccn.2021.5013
Restricted access

PARP inhibitors have been used to treat numerous diseases, but these agents have been approved the longest for use in ovarian cancer. All trials of PARP inhibitor maintenance in newly diagnosed ovarian cancer are positive for prolonged progression-free survival (PFS), but patients with BRCA mutations consistently derive the most benefit. Testing for homologous recombination deficiency may provide information regarding the degree of PFS benefit. In individuals without a BRCA mutation, PARP inhibition also prolongs PFS after chemotherapy for platinum-sensitive, PARP-naïve disease. As in the up-front setting, patients with BRCA mutations derive the most benefit in these trials. Finally, PARP inhibitors are active as monotherapy in PARP-naïve, BRCA-mutated relapsed disease, with increased activity observed in platinum-sensitive versus platinum-resistant disease.

Disclosures: Dr. Armstrong has disclosed serving as a scientific advisor for AbbVie, Inc.; and receiving grant/research support from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc., Pfizer Inc., and Syndax Pharmaceuticals Inc.

Correspondence: Deborah K. Armstrong, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 190, Baltimore, MD 21231. Email: armstde@jhmi.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Moore K , Colombo N , Scambia G , et al.. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495–2505.

  • 2.

    Ray-Coquard I , Pautier P , Pignata S , et al.. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381: 2416–2428.

  • 3.

    González-Martín A , Pothuri B , Vergote I , et al.. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381: 2391–2402.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Coleman RL , Fleming GF , Brady MF , et al.. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;381:2403–2415.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Mirza MR , Monk BJ , Herrstedt J , et al.. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154–2164.

  • 6.

    Pujade-Lauraine E , Ledermann JA , Selle F , et al.. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18:1274–1284.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Swisher EM , Lin KK , Oza AM , et al.. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18:75–87.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Moore KN , Secord AA , Geller MA , et al.. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20:636–648.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Drew Y , Penson RT , O’Malley DM , et al.. Phase II study of olaparib plus durvalumab and bevacizumab (MEDIOLA): initial results in patients with non-germline BRCA-mutated platinum sensitive relapsed ovarian cancer [abstract]. Ann Oncol 2020;31(Suppl 4):S615–616. Abstract 814MO.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Ledermann J , Harter P , Gourley C , et al.. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366: 1382–1392.

  • 11.

    Coleman RL , Oza AM , Lorusso D , et al.. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:1949–1961.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2021 by the National Comprehensive Cancer Network 2021
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2021
Online Publication Date:
17 May 2021

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1952 575 41
PDF Downloads 932 108 11
EPUB Downloads 0 0 0